CSIMarket
 


Eli Lilly And Company  (LLY)
Other Ticker:  
 
 

LLY's Net Income Growth by Quarter and Year

Eli Lilly And's Net Income results by quarter and year




LLY Net Income (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
IV Quarter December - 2,116.80 1,495.70 309.50
III Quarter September - 1,208.40 1,253.90 1,149.50
II Quarter June - 1,412.00 1,327.20 -259.90
I Quarter March 1,355.30 1,456.50 4,241.60 1,217.40
FY   1,355.30 6,193.70 8,318.40 2,416.50



LLY Net Income first quarter 2021 Y/Y Growth Comment
Eli Lilly And Company reported decrease in Net Income in the first quarter by -6.95% to $ 1,355.30 millions, from the same quarter in 2020.
The decrease in the first quarter Eli Lilly And Company's Net Income compares unfavorably to the Company's average Net Income rise of 27.06%.

Looking into first quarter results within Major Pharmaceutical Preparations industry 22 other companies have achieved higher Net Income growth. While Eli Lilly And Company' s Net Income decline of -6.95% ranks overall at the positon no. 1218 in the first quarter.




LLY Net Income ( Y/Y Growth %) 2021
2020 2019 2018
IV Quarter December - 41.53 % 383.26 % -
III Quarter September - -3.63 % 9.08 % 106.89 %
II Quarter June - 6.39 % - -
I Quarter March -6.95 % -65.66 % 248.41 % -
FY   - -25.54 % 244.23 % -

Financial Statements
Eli Lilly And's first quarter 2021 Net Income $ 1,355.30 millions LLY's Income Statement
Eli Lilly And's first quarter 2020 Net Income $ 1,456.50 millions Quarterly LLY's Income Statement
New: More LLY's historic Net Income Growth >>


LLY Net Income (Quarter on Quarter Growth %)

2021
2020 2019 2018
IV Quarter December - 75.17 % 19.28 % -73.08 %
III Quarter September - -14.42 % -5.52 % -
II Quarter June - -3.06 % -68.71 % -
I Quarter March -35.97 % -2.62 % 1270.47 % -
FY (Year on Year)   - -25.54 % 244.23 % -




Net Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #81
Overall #1218

Net Income Y/Y Growth Statistics
High Average Low
545.8 % 27.06 % -81.12 %
(Dec. 31, 2007)   (Dec. 31, 2006)
Net Income first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #23
Healthcare Sector #81
Overall #1218
Net Income Y/Y Growth Statistics
High Average Low
545.8 % 27.06 % -81.12 %
(Dec. 31, 2007)   (Dec. 31, 2006)

Net Income by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Eli Lilly And's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
1270.47 % 26.82 % -84.86 %
(Mar 31 2019)  


LLY's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2021 Eli Lilly And Company disclosed fall in Net Income from the previous quarter by -35.97% to $ 1,355.30 millions, from $ 2,116.80 millions declared in the previous quarter.

This is not important problem, as Eli Lilly And's Net Income always tend to plunge in the I. Quarter.

Within Major Pharmaceutical Preparations industry 7 other companies have achieved higher Net Income quarter on quarter growth. While Eli Lilly And's Net Income growth quarter on quarter, overall rank is 421.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #8
Healthcare Sector #30
Overall #421
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #8
Healthcare Sector #30
Overall #421
Net Income Q/Q Growth Statistics
High Average Low
1270.47 % 26.82 % -84.86 %
(Mar 31 2019)  


LLY's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2021 Eli Lilly And Company disclosed fall in Net Income from the forth quarter by -35.97% to $ 1,355.30 millions, from $ 2,116.80 millions achived in the previous quarter.

But that's not big issue, as Eli Lilly And's Net Income frequently tend to dip in this quarter.

Within Major Pharmaceutical Preparations industry 7 other companies have achieved higher Net Income quarter on quarter growth. While Eli Lilly And's Net Income growth quarter on quarter, overall rank is 421.


Eli Lilly And's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2021)
12 Months Ending
(Dec 31 2020)
12 Months Ending
(Sep 30 2020)
12 Months Ending
(Jun 30 2020)
12 Months Ending
(Mar 31 2020)
Cumulative Net Income 12 Months Ending $ 6,092.50 $ 6,193.70 $ 5,572.60 $ 5,618.10 $ 5,533.30
Y / Y Net Income Growth (TTM) 10.11 % -25.54 % -21.87 % -20.06 % 1.7 %
Year on Year Net Income Growth Overall Ranking # 446 # 1376 # 401 # 382 # 486
Seqeuential Net Income Change (TTM) -1.63 % 11.15 % -0.81 % 1.53 % -33.48 %
Seq. Net Income Growth (TTM) Overall Ranking # 439 # 263 # 371 # 230 # 1730




Cumulative Net Income growth Comment
Although Eli Lilly And's Annual Net Income growth year on year were below company's average 41.53% , Net Income announced in the Mar 31 2021 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 10.11% year on year, from -25.54% in Dec 31 2020.

Within the Healthcare sector 34 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 446, from total ranking in previous quarter at 1376.

Net Income TTM Q/Q Growth Statistics
High Average Low
125.15 %
4.19 %
-36.59 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 35
Overall # 446

Net Income TTM Y/Y Growth Statistics
High Average Low
1484.58 %
41.53 %
-79.77 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 35
S&P 500 # 439
Cumulative Net Income growth Comment
Although Eli Lilly And's Annual Net Income growth year on year were below company's average 41.53% , Net Income announced in the Mar 31 2021 period, show improvement in Net Income trend, to cumulative trailing twelve month growth of 10.11% year on year, from -25.54% in Dec 31 2020.

Within the Healthcare sector 34 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 446, from total ranking in previous quarter at 1376.

Net Income TTM Q/Q Growth Statistics
High Average Low
125.15 %
4.19 %
-36.59 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 8
Healthcare Sector # 35
Overall # 446

Net Income TTM Y/Y Growth Statistics
High Average Low
1484.58 %
41.53 %
-79.77 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 8
Sector # 35
S&P 500 # 439




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
LLY's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for LLY's Competitors
Net Income Growth for Eli Lilly And's Suppliers
Net Income Growth for LLY's Customers

You may also want to know
LLY's Annual Growth Rates LLY's Profitability Ratios LLY's Asset Turnover Ratio LLY's Dividend Growth
LLY's Roe LLY's Valuation Ratios LLY's Financial Strength Ratios LLY's Dividend Payout Ratio
LLY's Roa LLY's Inventory Turnover Ratio LLY's Growth Rates LLY's Dividend Comparisons



Companies with similar Net Income fall for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2021
Merck and Co Inc -1.03%$ -1.025 millions
Utah Medical Products Inc-3.69%$ -3.694 millions
Eli Lilly And Company-6.95%$ -6.948 millions
Amgen Inc -9.81%$ -9.808 millions
Baxter International Inc -9.91%$ -9.910 millions
Phibro Animal Health Corp-9.93%$ -9.925 millions
Alexion Pharmaceuticals Inc -12.27%$ -12.267 millions
Alpha Pro Tech Ltd-12.54%$ -12.541 millions
Atrion Corporation-13.17%$ -13.171 millions
Neurocrine Biosciences Inc -14.17%$ -14.171 millions
Avanos Medical Inc -16.42%$ -16.418 millions
Msa Safety Inc-16.44%$ -16.442 millions
National Research Corporation-21.46%$ -21.463 millions
Iradimed Corp-21.61%$ -21.612 millions
Corcept Therapeutics Inc-21.95%$ -21.952 millions
Catalyst Pharmaceuticals Inc -26.50%$ -26.501 millions
Stryker Corp-38.74%$ -38.742 millions
Teleflex Incorporated-42.92%$ -42.916 millions
Vyne Therapeutics Inc -48.92%$ -48.923 millions
Anika Therapeutics Inc -51.01%$ -51.010 millions
Viemed Healthcare Inc -60.31%$ -60.311 millions
Electromed Inc -65.75%$ -65.746 millions
Endo International Plc-68.04%$ -68.041 millions
Acadia Healthcare Company Inc -69.24%$ -69.240 millions
The Pennant Group Inc -69.36%$ -69.362 millions
Biogen Inc -70.95%$ -70.946 millions
Supernus Pharmaceuticals inc -73.54%$ -73.538 millions
Biomarin Pharmaceutical Inc-78.65%$ -78.655 millions
United Therapeutics Corporation-79.45%$ -79.448 millions
Align Technology inc -86.80%$ -86.801 millions


Economy


Advance Monthly Sales

Consumer Price Index CPI

Producer Price Index PPI

Retail Inventories

Personal Income

Gross Domestic Product GDP

Money Supply

Industrial Production

Productivity

Employment Situation

US International Trade

Factory Orders

Durable Goods

Construction Spending

Housing Starts

Vehicle Unit Sales

Stocks


Event Calendar

STTC's Profile

Stock Price

STTC's Financials

Business Description

Fundamentals

Charts & Quotes

STTC's News

Suppliers

STTC's Competitors

Customers & Markets

Economic Indicators

STTC's Growth

Company Segments

Screening


Stock Performance

Growth Rates

Profitability

Valuation

Dividend

Financial Strength

Efficiency

Largest Companies

Management Effectivness

Industries


At a Glance

Performance

Growth Rates

Profitability

Valuation

Financial Strength

Markets


At a Glance

Stocks

Indices

Sectors & Industries

Financials

Commodities

Currencies

News


At a Glance

Stocks

Economy

Industries

Other

Help


Sitemap

Advertise

About us

Glossary


Financial Terms

Technical Analysis

Fundamental Analysis

Energy Terms

Manufacturing Terms

Transportation Terms

Health Care

Insurance Terms

Economy Terms

Hotel & Leisure Terms

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.    Copyright © 2021 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
CSIMarket.com 1500 N. University Drive, Coral Springs, FL 33071